Literature DB >> 25813142

Preoperative ejection fraction determines early recovery of left ventricular end-diastolic dimension after aortic valve replacement for chronic severe aortic regurgitation.

Zhiwei Zhang1, Junjie Yang2, Yunsheng Yu1, Haoyue Huang1, Wenxue Ye1, Weiya Yan1, Han Shen1, Masaaki Ii3, Zhenya Shen4.   

Abstract

BACKGROUND: In patients with chronic severe aortic regurgitation (AR), aortic valve replacement (AVR) has been proved to promote left ventricular (LV) remodeling, especially LV end-diastolic dimension (LVEDD) reduction. However, there is little research whether postoperative LVEDD could return to normal parameter after AVR. The objective of this study was to determine predictors for the recovery of dilated LVEDD early after AVR.
METHODS: The echocardiographic data of 105 patients, who underwent AVR for chronic pure AR between January 2005 and December 2011, were analyzed at the preoperative (3-7 d), early (6-8 mo), and late (2-y) postoperative stages, retrospectively. According to the baseline level, LVEDD >70 mm or LV end-systolic dimension (LVESD) >50 mm or LVESD index >25 mm/m(2) were defined as severe LV dilation. Patients were then categorized into two groups (group 1: severe LV dilation; group 2: nonsevere LV dilation).
RESULTS: In all patients, four-fifth of the reduction in LV dimension occurred at early (6-8 mo) postoperative stage. The patients in both groups had significant decreases in the LVEDD and LVESD early after AVR, with an additional but insignificant reduction at late postoperative stage. The ejection fraction (EF) in both groups significantly increased at either early or late stage. However, the LVEDD and LVESD in group 1 were larger than those in group 2, and the EF in group 1 was lower than that in group 2 at early postoperative stage. By multivariate analysis, we found that the preoperative EF was a good predictor for the recovery of dilated LVEDD early after AVR (P = 0.009). Receiver-operating characteristics analysis showed that EF >52% was the best cut-off value for the recovery of LVEDD.
CONCLUSIONS: In patients with chronic pure AR, preoperative EF may be a good predictor for successful recovery of dilated LVEDD early after AVR.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aortic regurgitation; Aortic valve replacement; Ejection fraction; Left ventricular end-diastolic dimension; Recovery

Mesh:

Year:  2015        PMID: 25813142     DOI: 10.1016/j.jss.2015.02.069

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Isolated myxoid degeneration of aortic valve: diagnostic dilemma.

Authors:  Htay Htay Kyi; Kewan Hamid; Luay Alkotob; Thair Dawood
Journal:  BMJ Case Rep       Date:  2019-03-14

2.  Frequency of early remodeling of left ventricle and its comparison between patients with stroke volume ≥97 Ml versus patients with stroke volume <97 Ml after aortic valve replacement for severe aortic regurgitation.

Authors:  Hafiz Muhammad Farhan Ali Rizvi; Zaigham Rasool Khalid; Allah Baksh; Mirza Ahmad Raza Baig
Journal:  Pak J Med Sci       Date:  2016 Nov-Dec       Impact factor: 1.088

3.  Postoperative Assessment of Myocardial Function and Microcirculation in Patients with Acute Coronary Syndrome by Myocardial Contrast Echocardiography.

Authors:  Li Jiang; Hong Yao; Zhao-Guang Liang
Journal:  Med Sci Monit       Date:  2017-05-17

4.  Prognostic Impact of Left Ventricular Ejection Fraction in Patients With Moderate Aortic Regurgitation: Potential Implications for Treatment Decision-Making.

Authors:  Qinghao Zhao; Bin Zhang; Yunqing Ye; Zhe Li; Qingrong Liu; Rui Zhao; Zhenyan Zhao; Weiwei Wang; Zikai Yu; Haitong Zhang; Zhenya Duan; Bincheng Wang; Junxing Lv; Shuai Guo; Yanyan Zhao; Runlin Gao; Haiyan Xu; Yongjian Wu
Journal:  Front Cardiovasc Med       Date:  2022-01-17

5.  Prognostic factors associated with postoperative adverse outcomes in patients with aortic valve prolapse.

Authors:  Yanping Ruan; Xiaowei Liu; Xu Meng; Haibo Zhang; Yihua He
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.